Wu Qinchao, Wang Chen, Huang Chao, Li Dan
Nursing Teaching and Research Office, West Anhui Health Vocational College, Lu'an, China.
Department of Pediatric Internal, Affiliated Hospital of Anhui West Health Vocational College, Lu'an, China.
Transl Cancer Res. 2024 Jun 30;13(6):2779-2789. doi: 10.21037/tcr-23-2296. Epub 2024 Jun 11.
The comparative diagnostic performance of [Ga]Ga-fibroblast activation protein inhibitors-04 {[Ga]Ga-FAPI-04} positron emission tomography (PET) and fluorodeoxyglucose F 18 {[F]FDG} PET in identifying cancer recurrence remains uncertain. The purpose of our study was to compare the diagnostic performance of [Ga]Ga-FAPI-04 PET and [F]FDG PET imaging in cancer recurrence.
Up until March 1, 2024, we searched PubMed, Embase, and Web of Science for pertinent papers. Studies examining the diagnostic utility of [Ga]Ga-FAPI-04 PET and [18F]FDG PET for cancer recurrence were included. Using a bivariate fixed-effect model and random-effect model, the pooled sensitivity and specificity for [Ga]Ga-FAPI-04 PET and [F]FDG PET were reported as estimates with 95% confidence intervals (CIs). The I2 statistic was used to evaluate the heterogeneity among the pooled studies. The included studies' quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) approach.
In all, 508 papers were found during the first search; ultimately, 12 studies totaling 224 patients were included. The pooled sensitivity of [Ga]Ga-FAPI-04 PET and [F]FDG PET for cancer recurrence were 0.97 (95% CI: 0.90-1.00) and 0.69 (95% CI: 0.60-0.77). The pooled sensitivity of [Ga]Ga-FAPI-04 PET and [F]FDG PET for gastrointestinal cancer recurrence were 1.00 (95% CI: 0.97-1.00) and 0.57 (95% CI: 0.42-0.74). The pooled specificity of [Ga]Ga-FAPI-04 PET and [F]FDG PET for gastrointestinal cancer recurrence were 0.66 (95% CI: 0.15-1.00) and 0.46 (95% CI, 0.00-1.00).
Based on the previous studies, [Ga]Ga-FAPI-04 PET shows higher sensitivity compared to [F]FDG PET in detecting tumor recurrence, especially in detecting gastrointestinal cancer recurrence. [Ga]Ga-FAPI-04 PET shows similar specificity compared to [F]FDG PET in detecting gastrointestinal cancer recurrence. The detection results, however, came from investigations using modest sample numbers. In this matter, more extensive prospective study is required.
[镓]Ga-成纤维细胞活化蛋白抑制剂-04{[镓]Ga-FAPI-04}正电子发射断层扫描(PET)与氟代脱氧葡萄糖F 18{[氟]FDG}PET在识别癌症复发方面的比较诊断性能仍不确定。我们研究的目的是比较[镓]Ga-FAPI-04 PET和[氟]FDG PET成像在癌症复发中的诊断性能。
截至2024年3月1日,我们在PubMed、Embase和Web of Science上搜索相关论文。纳入研究[镓]Ga-FAPI-04 PET和[18F]FDG PET对癌症复发诊断效用的研究。使用双变量固定效应模型和随机效应模型,报告[镓]Ga-FAPI-04 PET和[氟]FDG PET的合并敏感性和特异性估计值及95%置信区间(CI)。I2统计量用于评估合并研究间的异质性。采用诊断准确性研究质量评估-2(QUADAS-2)方法评估纳入研究的质量。
首次搜索共找到508篇论文;最终纳入12项研究,共224例患者。[镓]Ga-FAPI-04 PET和[氟]FDG PET对癌症复发的合并敏感性分别为0.97(95%CI:0.90-1.00)和0.69(95%CI:0.60-0.77)。[镓]Ga-FAPI-04 PET和[氟]FDG PET对胃肠道癌症复发的合并敏感性分别为1.00(95%CI:0.97-1.00)和0.57(95%CI:0.42-0.74)。[镓]Ga-FAPI-04 PET和[氟]FDG PET对胃肠道癌症复发的合并特异性分别为0.66(95%CI:0.15-1.00)和0.46(95%CI,0.00-1.00)。
基于先前的研究,[镓]Ga-FAPI-04 PET在检测肿瘤复发方面显示出比[氟]FDG PET更高的敏感性,尤其是在检测胃肠道癌症复发方面。[镓]Ga-FAPI-04 PET在检测胃肠道癌症复发方面与[氟]FDG PET显示出相似的特异性。然而,检测结果来自样本量较小的研究。在这方面,则需要更广泛的前瞻性研究。